Alnylam Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Alnylam Pharmaceuticals şirketinin toplam hissedar öz sermayesi $32.4M ve toplam borcu $2.4B olup, bu da borç-öz sermaye oranını 7566.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $4.2B ve $4.2B dir.

Anahtar bilgiler

7,566.4%

Borç/özkaynak oranı

US$2.45b

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.78b
Eşitlik	US$32.35m
Toplam yükümlülükler	US$4.17b
Toplam varlıklar	US$4.21b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18

Alnylam's Huge Opportunity

Jan 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ALNY 'nin kısa vadeli varlıkları ( $3.4B ) kısa vadeli yükümlülüklerini ( $1.2B ) aşıyor.

Uzun Vadeli Yükümlülükler: ALNY şirketinin kısa vadeli varlıkları ( $3.4B ) uzun vadeli yükümlülüklerini ( $3.0B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ALNY şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ALNY şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 7566.4% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan ALNY mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: ALNY kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 19.9 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 03:05
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Alnylam Pharmaceuticals, Inc. 66 Bu analistlerden 30, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ishan Majumdar	Baptista Research
Huidong Wang	Barclays
Emily Bodnar	Berenberg

Alnylam Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You

CEO & Director recently sold US$1.3m worth of stock

Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Consensus EPS estimates upgraded to US$2.06 loss

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Price target increased by 8.3% to US$281

Consensus revenue estimates increase by 15%

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

CEO & Director notifies of intention to sell stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$1.9m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$243

RNAi: Winning In The Clinic, Now For The Market

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Key Executive notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.52 loss per share (vs US$1.40 loss in 1Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

Co-Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 10%

CEO & Director recently sold US$1.0m worth of stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam's Huge Opportunity

Forecast to breakeven in 2026

Chief Innovation Officer notifies of intention to sell stock

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Consensus revenue estimates increase by 28%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

No longer forecast to breakeven

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Consensus EPS estimates fall by 10%

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Insider notifies of intention to sell stock

CEO & Director recently sold US$1.5m worth of stock

Forecast to breakeven in 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$5.98 loss, revenue downgraded

President exercised options and sold US$4.7m worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$1.2m worth of stock